Physician profile
Kulveen Sachdeva
NPI 1790718138
$2,243.78
in general payments reported to CMS, 2019-2025
13 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $600 · 2021: $658 · 2022: $73.79 · 2023: $69.41 · 2024: $218 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $736.12 | 2019-2021 | |
| Abbvie INC. | $455.34 | 2021-2025 | Botox |
| Allergan, INC. | $380.00 | 2020-2021 | |
| Eisai INC. | $244.03 | 2022-2025 | |
| Amgen INC. | $125.00 | 2019 | |
| Mdd US Operations, LLC | $103.86 | 2023-2024 | Apokyn |
| Lilly USA, LLC | $61.30 | 2019-2025 | Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $32.21 | 2024-2025 | Crexont |
| Sanofi-Aventis U.S. LLC | $30.56 | 2021 | |
| Biogen, INC. | $27.02 | 2021-2022 | |
| Acorda Therapeutics, INC | $24.12 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kulveen Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.